Triple agonist: difference between revisions
Diff·revision 18 → 19·08:28, 21 Aug 2025
Difference between revision 18 and revision 19 of Triple agonist. 3 lines changed; the page grew by 282 bytes.
| Revision 18 — 22:12, 28 Jul 2025 ReceptorRhoda (talk) clarify that the peptide backbone is acylated rather than PEGylated 3,987 bytes ±0 | Revision 19 — 08:28, 21 Aug 2025 ComparisonCato (talk) state plainly that the research-use-only form is not approved for human use 4,269 bytes +282 | ||
|---|---|---|---|
| 32 | Material sold under these names by research-chemical suppliers is unapproved and, having no marketed reference product, has no generally available [[Reference standard|reference standard]] for identity confirmation. See [[Research use only]].{{r|usp1503}} | 32 | Material sold under these names by research-chemical suppliers is unapproved and, having no marketed reference product, has no generally available [[Reference standard|reference standard]] for identity confirmation. See [[Research use only]].{{r|usp1503}} |
| 33 | 33 | ||
| + | 34 | This wiki does not represent investigational compounds as suitable for human administration, and nothing here is medical advice.{{r|reports}} | |
| + | 35 | ||
| 34 | == References == | 36 | == References == |
| 35 | {{reflist}} | 37 | {{reflist}} |
| ⋮ | ⋮ | ||
| 37 | <ref name="jastreboff2023">Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial." ''New England Journal of Medicine'' 389(6):514–526 (2023). PMID 37366315.</ref> | 39 | <ref name="jastreboff2023">Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial." ''New England Journal of Medicine'' 389(6):514–526 (2023). PMID 37366315.</ref> |
| 38 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 40 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| + | 41 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> | |
| 39 | 42 | ||
| 40 | == See also == | 43 | == See also == |